Cytek Biosciences Inc. (CTKB) Stock Falls on Q4 2025 Earnings

Cytek Biosciences Inc. (CTKB) reported fourth-quarter 2025 revenue of $62.1 million, up 8.1% year-over-year and above the consensus revenue estimate of $58.3 million.

Key income statement highlights:

Gross profit: $32.9 million, down 2.3% year-over-year.

Cost of sales: $29.3 million, up 22.8% year-over-year.

Operating loss: $5.6 million, a deterioration of 287.3% year-over-year.

Net loss attributable to common shareholders: $44.8 million, change of +644.2% year-over-year.

Diluted earnings per share: -0.34, versus an estimate of -0.04.

Cash flow and balance sheet highlights:

Cash and cash equivalents: $90.9 million, down 8.0% year-over-year.

Cash used in operating activities: $580,000, a decline of 129.0% year-over-year.

Purchases of property, plant and equipment: $829,000, down 76.5% year-over-year.

Total liabilities: $119.8 million, up 15.5% year-over-year.

Overall, the quarter delivered revenue growth and a revenue beat, while profitability and operating cash flow worsened sharply; shares were down 1.82% since market close.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Cytek Biosciences Inc. Hedge Fund Activity

We have seen 72 institutional investors add shares of Cytek Biosciences Inc. stock to their portfolio, and 97 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BOSTON PARTNERS added 4,971,126 shares (+13369.4%) to their portfolio in Q4 2025, for an estimated $25,104,186
BROWN CAPITAL MANAGEMENT LLC removed 2,885,101 shares (-58.2%) from their portfolio in Q4 2025, for an estimated $14,569,760
WELLINGTON MANAGEMENT GROUP LLP removed 1,776,767 shares (-69.9%) from their portfolio in Q4 2025, for an estimated $8,972,673
MILLENNIUM MANAGEMENT LLC added 1,334,065 shares (+39.0%) to their portfolio in Q4 2025, for an estimated $6,737,028
RUSSELL INVESTMENTS GROUP, LTD. added 841,614 shares (+527.6%) to their portfolio in Q4 2025, for an estimated $4,250,150
BANK OF AMERICA CORP /DE/ added 686,001 shares (+403.2%) to their portfolio in Q4 2025, for an estimated $3,464,305
BLACKROCK, INC. added 625,335 shares (+3.8%) to their portfolio in Q4 2025, for an estimated $3,157,941

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Cytek Biosciences Inc. Government Contracts

We have seen $1,063,739 of award payments to $CTKB over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

Cytek Biosciences Inc. Analyst Ratings

Wall Street analysts have issued reports on $CTKB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

TD Cowen issued a "Buy" rating on 01/08/2026
Piper Sandler issued a "Overweight" rating on 11/11/2025

To track analyst ratings and price targets for Cytek Biosciences Inc., check out Quiver Quantitative's $CTKB forecast page.

Cytek Biosciences Inc. Price Targets

Multiple analysts have issued price targets for $CTKB recently. We have seen 2 analysts offer price targets for $CTKB in the last 6 months, with a median target of $6.25.

Here are some recent targets:

Brendan Smith from TD Cowen set a target price of $5.0 on 01/08/2026
David Westenberg from Piper Sandler set a target price of $7.5 on 11/11/2025